Pay in 4 interest-free payments of $6.10 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
CEO Mike Doustdar emphasized being very encouraged by the promising early uptake from the US launch of Wegovy pill and reiterated confidence in long-term volume growth
Overfill might sound like a bonus, but it actually indicates inconsistent manufacturing processes
Who Profits: Eli Lilly (LLY) FY2025 Revenue: $63.5B | GLP-1 Revenue (Mounjaro + Zepbound): $35-38B (estimated) | Operating Margin: 31% | CEO (David Ricks): $24.3M This issue's mechanism: Eli Lilly is winning the market share battle against Novo
We thank Robert Horvitz, William Schafer, Sreekanth Chalasani, and the Caenorhabditis Genetics Center (P40 OD010440) for sharing strains
Yes MT-2 activates the melanocortin-4 receptor pharmacologically, but when the peptide is removed, receptor signaling returns to baseline and appetite increases accordingly
Combination
US$ 28.75
US$ 22.45
US$ 28.52
US$ 27.00
US$ 27.67
US$ 28.07
